Back

Safety aspects and side effects of the novel lipid-lowering PCSK9 inhibitors evolocumab /alirozumab in atherosclerotic patients with familial hypercholesterolemia under lipid apheresis

19 April 2018 (00:00 - 00:00)
Organised by:
Congress Presentation Part of: Poster Session 1 - Lipids Lipids EAPC Premium Access EuroPrevent 2018

About the speaker

Photo
Mr Madan Raj Poudel

University Clinic OWL, Bielefeld (Germany)

9 More presentations in this session

Presentation thumbnail
Lipids - Poster discussant:
Presentation thumbnail
Improvement of lipid profile post cardiac rehabilitation according to the patient's level of risk in a tertiary hospital
Doctor A. Chauca Tapia (Barcelona, ES)
Presentation thumbnail
Efficacy of the PCSK9 inhibitors evolocumab/alirozumab in the reduction of LDL and Lp (a) in patients with familial hypercholesterolemia/manifest atherosclerosis in a real world setting
Mr M. Poudel (Bielefeld, DE)
Abstract Slides
Presentation thumbnail
Anti-PCSK9 in everyday clinical practice
Doctor R. Cadenas Chamorro (Madrid, ES)
Abstract Slides
Presentation thumbnail
Evaluation of LDL cholesterol level in patients with coronary artery disese after cardiac rehabilitation
Professor N. Mouine (Rabat, MA)
Abstract Slides

Access the full session

Session thumbnail
Poster Session 1 - Lipids

The Event

Event poster

EuroPrevent 2018

19 April - 21 April 2018
You may be interested in
thumbnail
Webinar
Unmet needs in lipid management: treatment goals and how to achieve them
thumbnail
Webinar
Risk assessment and lipid management in primary prevention
thumbnail
Congress Presentation
Making personalised prevention everyone's business

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources